Table 1. Baseline patient characteristics.
| No (%) | |
|---|---|
| Sex | |
| Male | 9 (50%) |
| Female | 9 (50%) |
| Age, median | 54 (range, 29–73) |
| Primary tumor site | |
| Head | 10 (55%) |
| Body or tail | 7 (39%) |
| Multicentric | 1 (6%) |
| Baseline CA19-9 | |
| Normal | 4 (22%) |
| >1 & ≤ 2 x UNL | 4 (22%) |
| >2 x UNL | 10 (56%) |
| Regional lymph node metastasis | 10 (56%) |
| No. of chemotherapy cycles | 6 (range, 3–13) |
| Surgery | 12 (67%) |
| R0 | 9 (75%) |
| R1 | 3 (25%) |
| Postoperative treatment (n = 12) | |
| No | 2 (17%) |
| Chemotherapy only | 7 (58%) |
| CCRT only | 2 (17%) |
| CCRT followed by chemotherapy | 1 (8%) |
| Postop chemotherapy regimen | |
| Gemcitabine | 3 (38%) |
| FOLFIRINOX | 5 (62%) |
UNL: upper normal limit; CCRT: concurrent chemoradiotherapy.